Mankind Pharma files DRHP for Rs 5,500 crore IPO

Mankind Pharma, the drug maker, recognized for Manforce Condoms and Prega News, has filed its draft purple herring prospectus (DRHP) with market regulator Sebi for an preliminary public providing on Friday. According to bankers, the scale of the general public supply is anticipated to be Rs 5,500 crore.

The firm’s preliminary public providing contains a proposal for the sale of 4 crore fairness shares by the promoters and present traders.

The supply for sale contains as much as 1 crore shares by promoter Juneja household, as much as 2 crore shares by Capital International, as much as 99.65 lakh by Beige, and as much as 50,000 fairness shares by Link Investment Trust.

The ChrysCapital-backed consortium of

of Singapore and CPP Investments owns 10% of Mankind, whereas Capital International owns one other 11% stake.

The firm has employed JM Morgan, Citi, Jefferies, Axis, IIFL, and Kotak as funding bankers.

The agency posted income of about Rs 8,000 crore and EBITDA of Rs 2,200 crore in FY22.

Mankind’s high over-the-counter (OTC) manufacturers embody being pregnant testing equipment Prega News, emergency contraception Unwanted-21, AcneStar anti-bacterial gel, Ringout anti-fungal powder, Gas-O-Fast, Kaloree 1 synthetic sweetener, Heal-O-Kind anti-bacterial ointment, Addiction Deodorant, and KabzEnd.

This can be one of many largest public points by a home drug producer after the Rs 6,480-crore IPO of

in 2020. Macleods Pharmaceuticals has additionally filed to lift Rs 5,000 crore via an preliminary public providing (IPO), whereas Pune-based Emcure Pharma is planning a Rs 4,500-crore IPO.

Leave a Reply

Your email address will not be published.